Clinical Trial Update: Post-Marketing Safety Study Following Long-Term Prophylactic OptivateTreatment in Subjects With Severe Haemophilia A [Phase 4]

View source ↗

Summary

Post-marketing safety study update for long-term prophylaxis with Optivate in severe Haemophilia A was terminated; results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Haemophilia

Drugs mentioned

• Optivate (von Willebrand factor concentrate (plasma-derived))

Snippet

Sponsor: Bio Products Laboratory | Conditions: Haemophilia A | Phase 4 | Status: TERMINATED | Results posted: 2021-07-22